Immutep Limited (ASX: IMM) is in the business of manufacturing biotechnology products, operating in Europe, Australia, and the U.S. The company develops immunotherapeutic products for the treatment of cancer, and autoimmune disease. The company helps in bringing innovative treatment options by leveraging its technology and expertise.
On 8th March 2019, the company declared that it had received positive results from its preclinical study for a novel LAG3 agonist antibody, named IMP761, that was being developed for the treatment of autoimmune diseases. The company chose the 14th Congress of European Crohn’s and Colitis Organisation (ECCO) Conference, to present its outstanding results of preclinical study of IMP761. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]
Consistent, with prior in vitro studies conducted by the company, on the immunosuppressive movement of IMP761, this new study in a non-human primate animal, demonstrated that IMP761 reduces inflammatory T cell infiltration, prompted by intra-dermal injections of an antigen.
Some of the conclusions from the in vivo study are mentioned below:
- Compared to control animals, CD3+ or CD8+ T cell infiltration was restrained by IMP761, for both tested subcutaneous dosages (0.03 mg/kg and 0.3 mg/kg) as watched through immunofluorescence staining of T cells, in the skin tissue test site biopsy.
- Multivariate analysis of the test site parameters (erythema, CD3, CD4 and CD8 T cell invasion) demonstrated, a critical decline of this antigen-specific T cell prompted intradermal reaction, when compared to the control group.
At the site of chronic inflammation, auto-immune memory T cells are stimulated by the similar self-peptide on a repetitive mode, gaining an “exhausted” phenotype. The company utilised LAG-3, a marker for depleted memory T cells, to focus on these self-reactive T cells in vivo. As LAG-3 is a T cell co-inhibitory receptor, the company developed an agonist antibody, IMP761, to expand LAG-3 down-modulation of T cell receptor signalling in these autoimmune system T cells.
Immutep CMO and CSO, Frédéric Triebel stated, “Future outlooks in developing more targeted immunosuppressive antibodies should address, the underlying driver of autoimmune diseases, by explicitly silencing the autoimmune memory T cells collecting at the disease site. By expanding, the physiological negative feedback loop of LAG-3 on T cell receptor signalling because of self-peptides, IMP761 is preventing the initiation of all downstream inflammatory pathways, such as the generation of TNF-?, IL6, IL-17 or IL-23.”
The company will progress IMP761 towards clinical advancement, based on the results of the in vivo study, which affirms the immunosuppressive activity of IMP761 on the inflammation related to antigen-induced T cell reaction, in non-human primate tissues. It has also, initiated CHO cell line progress for Good Manufacturing Practice manufacturing.
Earlier on 4th March 2019, the company presented the updates of its other products at Oppenheimer Healthcare Conference.
The stock of the company closed at A$0.035 as on 8th March 2019, up by 2.941% from the previous closing of A$0.034. The stock has given YTD return of more than 21%, and is up by, more than 13% in the last five days. Over the entire listing period, the company has delivered an impressive return of more than 536%.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.